The Phase 1a data de-risks the TH103 program and supports the ongoing Phase 1b/2 trial. The key catalyst is the Phase 1b/2 preliminary data expected in 1H 2027, which will inform dose selection for Phase 3. Traders should monitor enrollment updates and any safety signals from the multi-dose study.
Price Chart
Executive Summary
Kalaris Therapeutics reported positive expanded Phase 1a SAD data for TH103 in nAMD, showing a mean 9.2-letter BCVA gain and a mean 118µm CST reduction at Month 1 in 17 treatment-naïve patients. The data also showed 29% of patients required no retreatment over six months after a single injection, with PK data suggesting 27- to 53-fold lower systemic exposure vs. leading anti-VEGF agents. The filing is a clinical data update with no financial results; the company's cash runway is expected to fund operations into Q4 2027, with Phase 1b/2 data expected in 1H 2027.
Key Facts
- Expanded Phase 1a SAD dataset now includes 17 treatment-naïve nAMD patients; all 20 patients completed six-month follow-up.
- Mean 9.2-letter BCVA improvement and mean 118µm CST reduction at Month 1 after a single TH103 injection.
- 29% of treatment-naïve patients (5 of 17) received no additional anti-VEGF treatment during the entire six-month follow-up period.
- TH103 plasma Cmax was 27- to 53-fold lower than current leading anti-VEGF agents on a molar equivalence basis.
- No cases of intraocular inflammation (IOI) observed among six patients at the 2.5 mg dose with improved manufacturing process.
- Cash runway anticipated to fund company into Q4 2027; Phase 1b/2 data expected in 1H 2027.
Financial Impact
No financial results reported. Cash runway expected to fund operations into Q4 2027.
Risk Factors
- Phase 1b/2 multi-dose data may not replicate single-dose durability or safety profile.
- Manufacturing process refinements are ongoing; any impurity-related safety events could delay development.
- Cash runway only into Q4 2027; dilutive financing likely needed to fund Phase 3 trials.
- Competitive landscape includes established anti-VEGF agents (Eylea, Vabysmo) with large market share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-306737 |
| Document: d125006d8k.htm | 0001193125-26-306737 |
| Document: d125006dex991.htm | 0001193125-26-306737 |
| Document: 0001193125-26-306737-index-headers.html | 0001193125-26-306737 |
| Document: 0001193125-26-306737-index.html | 0001193125-26-306737 |
| Document: 0001193125-26-306737.txt | 0001193125-26-306737 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13G | $1.80 | awaiting T+60 | — | $1.86 (+3.33%) |
Aug 11, 2026 11w ago | 8-K | $3.97 | awaiting T+60 | — | $1.86 (−53.15%) |
Aug 11, 2026 11w ago | Press Release | $3.97 | awaiting T+60 | — | $1.86 (−53.15%) |
Aug 3, 2026 12w ago | 3 | $4.32 | awaiting T+60 | — | $1.86 (−56.94%) |
Jul 20, 2026 14w ago | 8-K | $4.00 $2.23 | ▼ −44.25% | ▼ −49.09% | $1.86 (−53.50%) |
Jul 17, 2026 14w ago | 8-K | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.86 (−57.53%) |
Jul 17, 2026 14w ago | Press Release | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.86 (−57.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.36 $3.90 | ▼ −10.55% | ▼ −14.95% | $1.86 (−57.34%) |
May 12, 2026 24w ago | 8-K | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.86 (−61.17%) |
May 12, 2026 24w ago | Press Release | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.86 (−61.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers